X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (543) 543
index medicus (542) 542
animals (365) 365
mice (264) 264
immunology (260) 260
female (200) 200
male (199) 199
interleukin-23 - antagonists & inhibitors (198) 198
psoriasis (184) 184
inflammation (180) 180
interleukin-23 - immunology (180) 180
interleukin-23 (175) 175
cytokines (174) 174
il-23 (169) 169
interleukin-23 - metabolism (168) 168
double-blind (139) 139
psoriasis - drug therapy (139) 139
antibodies, monoclonal - therapeutic use (126) 126
interleukins (124) 124
dendritic cells (118) 118
interleukin-17 - immunology (115) 115
t-cells (115) 115
middle aged (112) 112
mice, inbred c57bl (111) 111
ustekinumab (111) 111
adult (110) 110
interleukin-12 - antagonists & inhibitors (110) 110
interleukin-17 - metabolism (106) 106
dermatology (104) 104
cells, cultured (97) 97
psoriasis - immunology (91) 91
th17 cells - immunology (90) 90
expression (89) 89
interleukin-17 - antagonists & inhibitors (87) 87
cell biology (83) 83
il-17 (83) 83
tumor necrosis factor-alpha - antagonists & inhibitors (82) 82
interleukin-17 (81) 81
cytokine (80) 80
interleukin-23 - genetics (78) 78
article (77) 77
mice, knockout (77) 77
abridged index medicus (76) 76
interleukin 23 (76) 76
treatment outcome (76) 76
t cells (73) 73
disease models, animal (71) 71
interleukin-12/23 monoclonal-antibody (70) 70
signal transduction (69) 69
pharmacology & pharmacy (68) 68
interleukin-12 - immunology (64) 64
dendritic cells - immunology (62) 62
pathogenesis (61) 61
rheumatology (60) 60
th17 cells (60) 60
rheumatoid-arthritis (58) 58
severity of illness index (58) 58
biochemistry & molecular biology (57) 57
inflammatory-bowel-disease (57) 57
autoimmune inflammation (56) 56
interleukin-17 - genetics (56) 56
aged (55) 55
analysis (55) 55
gene expression (54) 54
interleukin-12 (54) 54
lymphocytes (54) 54
efficacy (53) 53
arthritis (52) 52
cells (52) 52
differentiation (52) 52
antibodies, monoclonal - adverse effects (51) 51
care and treatment (51) 51
medicine, research & experimental (48) 48
activation (47) 47
interferon-gamma (47) 47
placebo-controlled trial (47) 47
th17 (47) 47
dendritic cells - metabolism (46) 46
ifn-gamma (46) 46
rodents (46) 46
safety (46) 46
antibodies, monoclonal - pharmacology (45) 45
antibodies, monoclonal, humanized - therapeutic use (45) 45
cytokines - metabolism (45) 45
research (45) 45
t-lymphocytes - immunology (45) 45
inflammation - immunology (44) 44
interleukin-23 - biosynthesis (44) 44
cd4-positive t-lymphocytes - immunology (43) 43
disease (43) 43
enzyme-linked immunosorbent assay (43) 43
il-12 (43) 43
inflammatory bowel disease (43) 43
lymphocytes t (43) 43
mice, inbred balb c (43) 43
tgf-beta (43) 43
interleukin-12 - metabolism (42) 42
health aspects (41) 41
immune system (41) 41
interleukins - immunology (41) 41
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
British Journal of Dermatology, ISSN 0007-0963, 08/2016, Volume 175, Issue 2, pp. 247 - 248
Journal Article
Cytokine, ISSN 1043-4666, 10/2016, Volume 86, pp. 92 - 99
This is a review looking at anti cytokine therapy in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PSA) and Ankylosing Spondylitis (AS). The review explores... 
Ankylosing Spondylitis | Rheumatoid Arthritis | Inflammatory arthritis | TNFα inhibitor | Cytokine | IL27 | Psoriatic Arthritis | ACTIVE RHEUMATOID-ARTHRITIS | INADEQUATE RESPONSE | BIOCHEMISTRY & MOLECULAR BIOLOGY | PHASE-II | MONOCLONAL-ANTIBODY | ANKYLOSING-SPONDYLITIS | IMMUNOLOGY | PSORIATIC-ARTHRITIS | TOFACITINIB CP-690,550 | PROOF-OF-CONCEPT | CELL BIOLOGY | DOUBLE-BLIND | TNF alpha inhibitor | PLACEBO-CONTROLLED TRIAL | Interleukin-6 - therapeutic use | Cytokines - metabolism | Interleukin-27 - antagonists & inhibitors | Arthritis, Psoriatic - physiopathology | Humans | Spondylitis, Ankylosing - drug therapy | Spondylitis, Ankylosing - physiopathology | Janus Kinases - antagonists & inhibitors | Spondylitis, Ankylosing - immunology | Animals | Arthritis, Psoriatic - immunology | Interleukin 1 Receptor Antagonist Protein - therapeutic use | Interleukin-17 - antagonists & inhibitors | Arthritis, Rheumatoid - drug therapy | Interleukin-23 - antagonists & inhibitors | Arthritis, Psoriatic - drug therapy | Interleukin-12 - antagonists & inhibitors | Mice | Cytokines - antagonists & inhibitors | Arthritis, Rheumatoid - immunology | Arthritis, Rheumatoid - physiopathology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Chronic Disease - drug therapy | Rheumatoid factor | Arthritis | Psoriasis | Cytokines | Medical colleges | Medical research | Medicine, Experimental
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2013, Volume 8, Issue 12, p. e84634
Psoriasis is a complex inflammatory disease resulting from the activation of T helper (Th) 1 and Th17 cells. Recent evidence suggests that abnormal activation... 
SIGNALING PATHWAYS | IN-VITRO | MULTIDISCIPLINARY SCIENCES | KERATINOCYTES | EPIDERMAL HYPERPLASIA | ANTIMICROBIAL PEPTIDES | PLASMACYTOID DENDRITIC CELL | EXPRESSION | T-CELLS | PSORIASIS-VULGARIS | INNATE IMMUNITY | RNA, Messenger - immunology | Interleukin-23 - toxicity | Toll-Like Receptor 7 - antagonists & inhibitors | Toll-Like Receptor 9 - antagonists & inhibitors | Dermatitis - immunology | Gene Expression Regulation - immunology | Dermatitis - prevention & control | Gene Expression Regulation - drug effects | Toll-Like Receptor 9 - immunology | Dermatitis - pathology | Signal Transduction - immunology | Toll-Like Receptor 8 - immunology | Animals | Membrane Glycoproteins - antagonists & inhibitors | Toll-Like Receptor 8 - antagonists & inhibitors | Signal Transduction - drug effects | Toll-Like Receptor 7 - immunology | Th17 Cells - immunology | Female | Mice | Membrane Glycoproteins - immunology | Th17 Cells - pathology | Keratin | Psoriasis | Genes | Skin | Inflammation | B cells | Comparative analysis | Gene expression | Dermatitis | Laboratories | Pathogenesis | Hyperplasia | Helper cells | Interleukin 23 | Activation | Antagonists | Lymphocytes T | Kinases | Proteins | Genotype & phenotype | Receptors | Psoriasis vulgaris | Pathways | Lymphocytes | Rodents | Modulation | Toll-like receptors | Skin diseases | Lesions | Growth factors | Immune system | Antigens | Cytokines | Dendritic cells | Dermatology | Injection | Interleukin 17 | Signaling | Aberration | Pharmaceuticals
Journal Article
Proteins: Structure, Function, and Bioinformatics, ISSN 0887-3585, 06/2014, Volume 82, Issue 6, pp. 975 - 989
Journal Article
Journal of Immunology, ISSN 0022-1767, 01/2012, Volume 188, Issue 2, pp. 753 - 764
Journal Article
Journal Article
Immunity, ISSN 1074-7613, 10/2015, Volume 43, Issue 4, pp. 739 - 750
Interleukin-23 (IL-23) and IL-17 are cytokines currently being targeted in clinical trials. Although inhibition of both of these cytokines is effective for... 
INFLAMMATORY-BOWEL-DISEASE | CHRONIC PLAQUE PSORIASIS | CROHNS-DISEASE | EPITHELIAL-CELLS | COLITIS | LIPOPOLYSACCHARIDE-BINDING PROTEIN | DOUBLE-BLIND | RECEPTOR COMPLEX | IMMUNOLOGY | T-CELLS | TH17 CELLS | T-Lymphocyte Subsets - immunology | Interleukin-23 Subunit p19 - antagonists & inhibitors | Intestinal Mucosa - physiopathology | ATP Binding Cassette Transporter, Sub-Family B - deficiency | Receptors, Interleukin-17 - immunology | Epithelium - physiopathology | Interleukin-17 - immunology | Interleukin-17 - physiology | Transcriptome | Helicobacter Infections - complications | Interleukin-12 Subunit p40 - antagonists & inhibitors | T-Lymphocytes, Regulatory - immunology | Receptors, Interleukin-17 - physiology | Female | Colitis - drug therapy | Colitis - immunology | Interleukin-23 - physiology | Disease Models, Animal | Gene Expression Regulation - immunology | Immunoglobulin G - therapeutic use | Helicobacter Infections - immunology | Receptors, Interleukin-17 - antagonists & inhibitors | Permeability | Disease Progression | Interleukin-23 - immunology | Mice, Knockout | Colitis - etiology | Animals | Colitis - microbiology | Forkhead Transcription Factors - analysis | Immunization, Passive | Mice | Interleukin-23 Subunit p19 - immunology | Colitis | Psoriasis | Interleukins | Drug resistance | Analysis | Mortality | Inflammatory bowel disease | Studies | Pathology | Flow cytometry | Immunoglobulins | Histopathology | Cytokines | Infections | Inflammation | Gene expression | Crohns disease
Journal Article
Annals of the New York Academy of Sciences, ISSN 0077-8923, 03/2011, Volume 1222, Issue 1, pp. 30 - 39
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10080, pp. 1699 - 1709
Summary Background The interleukin-23 pathway is implicated genetically and biologically in the pathogenesis of Crohn's disease. We aimed to assess the... 
Internal Medicine | TRIAL | CELLS | MEDICINE, GENERAL & INTERNAL | ANTI-TNF | INFLAMMATORY-BOWEL-DISEASE | EFFICACY | ULCERATIVE-COLITIS | NECROSIS-FACTOR ANTAGONISTS | ANTITUMOR | MAINTENANCE THERAPY | FACTOR-ALPHA | Severity of Illness Index | Interleukin-23 Subunit p19 - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gastrointestinal Agents - administration & dosage | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Remission Induction | Dose-Response Relationship, Drug | Young Adult | Antibodies, Monoclonal - administration & dosage | Crohn Disease - drug therapy | Adolescent | Gastrointestinal Agents - therapeutic use | Adult | Female | Aged | Gastrointestinal Agents - adverse effects | Clinical trials | Monoclonal antibodies | Medicine, Experimental | Medical research | Interleukins | Intravenous administration | Pathogenesis | Mucosa | Interleukin | Interleukin 23 | Antagonists | Intravenous therapy | Randomization | Endoscopes | Motivation | Gastroenterology | Remission | Tumor necrosis factor-TNF | Colon | Safety | Active control | Chronic illnesses | Psoriasis | Cytokines | Ileitis | Nausea | Inflammation | Crohn's disease | Disease control | Patients | Ileum | Crohns disease | Inflammatory bowel disease | Interactive systems | Tumor necrosis factor | Ulcers | TNF inhibitors | Tumors
Journal Article